Abstract: The present disclosure discloses a preparation method of an aluminum nitride (AlN) composite structure based on a two-dimensional (2D) crystal transition layer. The preparation method of the present disclosure includes: transferring the 2D crystal transition layer on a first periodic groove of an epitaxial substrate; forming a second periodic groove staggered with the first periodic groove on the 2D crystal transition layer; depositing a supporting protective layer; depositing a functional layer of a required AlN-based material; and removing the 2D crystal transition layer through thermal oxidation to obtain a semi-suspended AlN composite structure. The preparation method of the present disclosure has low difficulty and is suitable for large-scale industrial production.

Abstract: A color conversion panel and a display device are provided. The color conversion panel includes an opaque substrate and a sapphire substrate. The opaque substrate includes a plurality of first pixel openings, a plurality of second pixel openings and a plurality of third pixel openings. The first pixel openings are filled with red quantum dot material, and the second pixel openings are filled with green quantum dot material. The sapphire substrate is on the opaque substrate. A first surface of the sapphire substrate that faces the opaque substrate has a plurality of first arc surfaces corresponding to the first pixel openings, a plurality of second arc surfaces corresponding to the second pixel openings, and a plurality of third arc surfaces corresponding to the third pixel openings.

Abstract: A light-emitting element includes a pair of electrodes, a first light-emitting unit, a second light-emitting unit, and a charge generation layer. The first light-emitting unit, between the pair of electrodes, and the first light-emitting unit, includes a first light-emitting layer. The second light-emitting unit, between the pair of electrodes, includes a second light-emitting layer. A first luminescent layer includes a first main body material, a second main body material, a first guest material, and a first auxiliary material, and the first main body material forms a first excimer complex with the second main body material. A first excited triplet state energy level of the first auxiliary material is lower than a first excited triplet state energy level of the first excimer complex, and the first excited triplet state energy level of the first auxiliary material is higher than that of the first guest material.

Abstract: Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: Described herein are conductive elastomeric foam materials and methods of making and using the same. The conductive elastomeric foam materials include a polymeric matrix, one or more conductive fillers, and one or more foaming agents. The polymeric matrix can include a thermoset polymer or a thermoplastic polymer. Also described herein are methods of making conductive elastomeric foam materials. Further described herein are molded products including the conductive elastomeric foam materials as described herein and wearable devices including the molded products.

Abstract: An oligopeptide with lipid-lowering activity, a preparation method and an application thereof are provided, belonging to the field of biotechnology. The amino acid sequence of the oligopeptide with lipid-lowering activity is shown in SEQ ID NO: 1. The preparation method includes the following steps: (1) hydrolyzing a loach protein with proteases to obtain an enzymatic hydrolysis product; (2) separating the enzymatic hydrolysis product using an ultrafiltration membrane, and taking a component with a molecular weight less than 3 kilodalton (kDa); and (3) filtering and separating the component with the molecular weight less than 3 kDa by Sephadex G-15 to obtain the oligopeptide. The oligopeptide is derived from the loach protein and has the characteristics of high safety, high efficiency, and wide sources.

Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

Abstract: A tile or plate, includes: an upper plate (3) and a lower plate (4); wherein a plurality of heat conducting cavities (6) are uniformly provided between the upper plate (3) and the lower plate (4) via connecting ribs (5). A solar collection layer is provided on an upper surface of the tile or the plate. Two ends of the tile or the plate are connected with each of the plurality of the heat conducting cavities (6) via transverse connecting pipes (23, 37, 42). The transverse connecting pipes (23, 37, 42) of two neighboring tiles are connected by a ferrule (17) or a hose (36) to form an integrated circulation system. The tile or plate has a large day-lighting area and a high energy conversion rate.

Abstract: Provided is a method for manufacturing cell-containing blocks having steps of: preparing an standardized size mold by 3D printing (three dimensional printing) using a biocompatible elastic material; injecting a thermosensitive colloid into the mold to form a thermosensitive mold; injecting a hydrogel containing cells in to the thermosensitive mold and curing the hydrogel containing cells to form the cell-containing blocks; separating the thermosensitive mold and the cell-containing blocks at a temperature higher than a solidifying point of the thermosensitive colloid. Also provided are method for assembling the cell-containing blocks in a target configuration by using an assembling mold defining the target configuration and made of a thermoreversible material.

Abstract: An efficient electronic structure for circuit design, testing and/or manufacture for validating a cell layout design using an intelligent engine trained using selectively arranged cells selected from a cell library. An initial design rule violation (DRV) prediction engine is initially trained using a plurality of pin patterns generated by predefined cell placement combinations, where pin patterns are pixelized and quantified and is classified as either (i) a DRV pin pattern (i.e., pin patterns likely to produce a DRV) or (ii) a DRV-clean pin pattern (i.e., pin patterns unlikely to produce a DRV).

Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.

Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

Abstract: An efficient electronic structure for circuit design, testing and/or manufacture for validating a cell layout design using an intelligent engine trained using selectively arranged cells selected from a cell library. An initial design rule violation (DRV) prediction engine is initially trained using a plurality of pin patterns generated by predefined cell placement combinations, where pin patterns are pixelized and quantified and is classified as either (i) a DRV pin pattern (i.e., pin patterns likely to produce a DRV) or (ii) a DRV-clean pin pattern (i.e., pin patterns unlikely to produce a DRV).

Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.

Abstract: A virtual reality-based ophthalmic inspection system includes a wearable unit, an electronic unit, and at least one detector. The wearable unit is available for an inspected object to wear the wearable unit on head. The electronic unit is assembled with the wearable unit and has a left-eye display zone and a right-eye display zone. A first visual acuity of the inspected object is identified according to a first eyesight information. The electronic unit performs a visual correction confirmation process, the at least one detector detects a condition value of corresponding the right eye and/or the left eye, and the electronic unit answers a first comparison result after comparing the condition value with a threshold value.

Abstract: A virtual reality-based ophthalmic inspection system includes a wearable unit, an electronic unit, and at least one detector; the wearable unit is available for an inspected object to wear the wearable unit on head; the electronic unit is assembled with the wearable unit and has a left-eye display zone and a right-eye display zone, wherein the left-eye display zone is used for displaying at least one left-eye sight-targets, and the right-eye display zone is used for displaying at least one right-eye sight-targets; the detector is disposed on the electronic unit. A sight-target with at least one distinguishing feature are shown on one of the left-eye display zone and the right-eye display zone, the left-eye display zone displays the sight-target while the right-eye display zone is filled with black, and the right-eye display zone displays the sight-target while the left-eye display zone is filled with black.

Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.

Abstract: The present invention relates to bispecific anti-TNF-?/IL-17A antibodies and anti-TNF-? antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Provided is a method for manufacturing cell-containing blocks having steps of: preparing an standardized size mold by 3D printing (three dimensional printing) using a biocompatible elastic material; injecting a thermosensitive colloid into the mold to form a thermosensitive mold; injecting a hydrogel containing cells in to the thermosensitive mold and curing the hydrogel containing cells to form the cell-containing blocks; separating the thermosensitive mold and the cell-containing blocks at a temperature higher than a solidifying point of the thermosensitive colloid. Also provided are method for assembling the cell-containing blocks in a target configuration by using an assembling mold defining the target configuration and made of a thermoreversible material.